Loading clinical trials...
Loading clinical trials...
A Multicenter Open-label, Prospective Study to Evaluate the Efficacy and Safety of SIRT Using Yttrium-90 Glass Microspheres Followed by Durvalumab and Tremelimumab for Treatment of Hepatocellular Carcinoma With Portal Vein Thrombosis
Conditions
Interventions
Selective Internal Radiotherapy
Tremelimumab
+1 more
Start Date
January 2, 2026
Primary Completion Date
January 2, 2030
Completion Date
January 2, 2030
Last Updated
August 14, 2025
NCT06707233
NCT05911633
NCT06187961
NCT06561399
NCT04224636
NCT06397222
Lead Sponsor
Center Eugene Marquis
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions